Derazantinib; ARQ-087

Inoa Kimia:

(6R)-6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-Benzo[h]quinazolin-2-amine

SMILES Code:

COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1

Code InChi:

InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24- 10-4-5-12-2 7(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H ,32,33,34)/t26-/m1/s1

Ki InChi:

KPJDVVCDVBFRMU-AREMUKBSSA-N

Hua'ōlelo:

Derazantinib, ARQ-087, ARQ087, ARQ 087, 1234356-69-4

Hiki ke hoʻoheheʻe:Hiki ke hoʻoheheʻe ʻia ma DMSO

Waihona:0 - 4°C no ka wā pōkole (nā lā i nā pule), a i ʻole -20°C no ka wā lōʻihi (mau mahina).

wehewehe:

ʻO Derazantinib, ka mea i kapa ʻia ʻo ARQ-087, he mea hoʻopaneʻe waha bioavailable o ka fibroblast growth factor receptor (FGFR) me ka hana antineoplastic. FGFR inhibitor ARQ 087 nakinaki a potently inhibits i ka hana o ka FGFR subtypes 1, 2 a me 3. Hiki i keia ke hoopau i ka FGFR-mediated signal transduction alahele, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells . ʻO FGFR, kahi mea hoʻokipa tyrosine kinase, ua hoʻoponopono ʻia i nā ʻano cell tumor he nui a he hana koʻikoʻi i ka hoʻonui ʻana o ka cellular tumor, ʻokoʻa, angiogenesis a me ke ola.

Pahuhopu: FGFR